Amcinonide

U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis

Retrieved on: 
Tuesday, March 24, 2020
Biotechnology, General Health, FDA, Health, Pharmaceutical, Medical specialties, Steroids, Chemistry, Type I hypersensitivity, RTT, Corticosteroids, Atopic dermatitis, Crisaborole, Atopy, Dermatitis, Dupilumab, Amcinonide, the CrisADe CARE 1 Study, Atopic Dermatitis, EUCRISA® (crisaborole) ointment, 2%

"The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients."

Key Points: 
  • "The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients."
  • EUCRISA may cause side effects including allergic reactions at or near the application site.
  • EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and pediatric patients 3 months of age and older.
  • 2Pfizer Inc. Pfizer Receives FDA Approval for EUCRISA (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema).

Bausch Health Announces U.S. Launch Of BRYHALI™ (halobetasol propionate) Lotion, 0.01%, For Plaque Psoriasis In Adults

Retrieved on: 
Wednesday, November 7, 2018
Health, Pharmacology, Skin care, RTT, Psoriasis, Clinical trial, Bausch Health, Food and Drug Administration, Lotion, Desonide, Amcinonide

The company received final approval from the U.S. Food and Drug Administration (FDA) for BRYHALI Lotion on Nov. 6, 2018.

Key Points: 
  • The company received final approval from the U.S. Food and Drug Administration (FDA) for BRYHALI Lotion on Nov. 6, 2018.
  • The FDA approval of BRYHALI Lotion was based on data from two prospective, multicenter, randomized, double-blind clinical trials.
  • Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.
  • BRYHALI Lotion is a prescription medicine used on the skin (topical) to treat adults with plaque psoriasis.

The Global Topical Corticosteroids Market is forescasted to grow at a CAGR of 5.94% during the period 2018-2022

Retrieved on: 
Friday, October 26, 2018
RTT, Autoimmune diseases, Immunology, Corticosteroids, Medicine, Psoriasis, Dermatitis, Topical steroid, Amcinonide

Topical corticosteroids are synthetic corticosteroids that are used for the treatment of skin-related diseases such as psoriasis, eczema, dermatitis, and itching.

Key Points: 
  • Topical corticosteroids are synthetic corticosteroids that are used for the treatment of skin-related diseases such as psoriasis, eczema, dermatitis, and itching.
  • Technavio's analysts forecast the Global Topical Corticosteroids Market to grow at a CAGR of 5.94% during the period 2018-2022.
  • The report covers the present scenario and the growth prospects of the topical corticosteroids market.
  • The market is divided into the following segments based on geography:
    Technavio's report, topical corticosteroids market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts.